BTG Pactual Asset Management US LLC Acquires New Stake in Becton, Dickinson and Company $BDX

Posted by Geri Gentry on Sep 1st, 2026

BTG Pactual Asset Management US LLC bought a new stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 2,864 shares of the medical instruments supplier’s stock, valued at approximately $433,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Imprint Wealth LLC purchased a new stake in shares of Becton, Dickinson and Company during the third quarter worth about $25,000. SHP Wealth Management purchased a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth approximately $29,000. Meeder Asset Management Inc. boosted its position in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 102 shares during the last quarter. Finally, Tucker Asset Management LLC purchased a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $34,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Michael Feld sold 165 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares in the company, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 9,105 shares of company stock worth $1,590,208 over the last three months. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $188.13 on Tuesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $193.07. The firm has a market capitalization of $51.84 billion, a P/E ratio of 56.67, a P/E/G ratio of 13.36 and a beta of 0.19. The business’s 50-day simple moving average is $167.10 and its 200-day simple moving average is $160.32.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the company earned $3.68 EPS. The company’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BDX. TD Cowen increased their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research report on Monday, July 6th. Barclays upped their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Jefferies Financial Group reissued a “buy” rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Finally, Piper Sandler lifted their price target on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $187.67.

Check Out Our Latest Research Report on BDX

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.